首頁 > 市場調查報告書 > 製藥

感染疾病

市場調查報告書

商品編碼

1983163

肝炎治療市場：依藥物類別、疾病類型、給藥途徑、通路和地區分類

Hepatitis Drugs Market, By Drug Class, By Disease Type, By Route of Administration, By Distribution Channel, By Geography

出版日期: 2026年02月02日 | 出版商:

Coherent Market Insights | 英文 152 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

據估計，2026年肝炎治療市場規模為263.8億美元，預計2033年將達到329.06億美元。預計2026年至2033年，該市場將以3.2%的複合年成長率成長。

報告範圍		報告詳情
基準年：	2025	2026年市場規模：	263.8億美元
歷史數據時期：	2020年至2024年	預測期：	2026年至2033年
2026年至2033年預測期間的複合年成長率：	3.20%	2033年市場規模預測：	329.06億美元

肝炎是指肝臟的發炎性疾病。肝炎是由病毒感染引起的肝臟感染疾病，包括甲型、B型、丙型、丁型和戊型肝炎。甲型肝炎是一種急性、短期疾病，而B型、C型和丁型肝炎則為持續性疾病，且極易發展為慢性疾病。戊型肝炎通常為急性，但對孕婦尤其危險，可能增加孕產婦和胎兒的死亡率和發病率。

市場動態

全球肝炎盛行率的上升預計將推動肝炎治療市場的成長。根據世界衛生組織（世衛組織）統計，2015年全球有2.57億人患有慢性B型肝炎，2016年新增乙型肝炎病例450萬例（佔總人口的16.7%）。乙型肝炎可透過安全有效的疫苗預防。此外，世衛組織的目標是到2030年消除病毒性肝炎，其中包括將全球新感染病例減少90%，並將病毒性肝炎死亡人數減少65%。

然而，肝炎治療藥物研發和核准所需的時間等因素預計將在預測期內阻礙肝炎治療市場的成長。例如，根據美國國家生物技術資訊中心 (NCBI) 2017 年的一份報告，從標靶識別到上市核准，一種新肝炎藥物的研發需要超過 12 年的時間。

本次調查的主要特點。

本報告對肝炎治療市場、市場規模以及 2026 年至 2033 年的預測期內的複合年成長率 (%) 進行了詳細分析，以 2025 年為基準年。
本報告指出了各個細分市場的潛在商機，並說明了該市場中具有吸引力的投資提案矩陣。
此外，本研究還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域展望以及主要企業採取的競爭策略的重要見解。
本報告根據以下參數對全球肝炎治療市場的主要企業進行了分析：公司概況、財務表現、產品系列、地理企業發展、分銷策略、關鍵發展和策略。
透過利用本報告中的見解，企業行銷負責人和經營團隊可以就未來的產品發布、政府舉措、技術升級、市場擴張和行銷策略做出明智的決策。
本報告面向該行業的眾多相關人員，包括投資者、產品製造商、經銷商、供應商、研究和諮詢公司、新參與企業和金融分析師。

北美洲
- 美國
- 加拿大
歐洲
- 英國
- 德國
- 義大利
- 法國
- 西班牙
- 俄羅斯
- 其他歐洲國家
亞太地區
- 中國
- 日本
- 印度
- ASEAN
- 澳洲
- 韓國
- 亞太其他地區
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲
非洲
- 北非
- 中非
- 南非
中東
- 海灣合作理事會國家
- 以色列
- 其他中東國家

第9章競爭情勢

公司簡介
- Merck &Co. Inc.
- Gilead Sciences Inc.
- AbbVie Inc.
- Bristol Myers Squibb Company
- F. Hoffmann-La Roche Ltd.
- LAURUS Labs
- Zydus Cadila
- Hetero Healthcare Limited
- GlaxoSmithKline PLC.
- Cipla Inc.

第10章

參考
調查方法

簡介目錄

Product Code: CMI2977

Hepatitis Drugs Market is estimated to be valued at USD 26,380 Mn in 2026 and is expected to reach USD 32,906 Mn by 2033, growing at a compound annual growth rate (CAGR) of 3.2% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 26,380 Mn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	3.20%	2033 Value Projection:	USD 32,906 Mn

Hepatitis refers to an inflammatory condition of the liver. Viral infections of the liver classified as hepatitis include hepatitis A, B, C, D, and E. Hepatitis A is an acute, short-term disease, while hepatitis B, C, and D are most likely to become ongoing and chronic. Hepatitis E is usually acute but can be particularly dangerous in pregnant women which increase maternal and fetal mortality and morbidity.

Market Dynamics

Increasing prevalence of hepatitis worldwide is expected to boost growth of the hepatitis drugs market. According to World Health Organization (WHO), in 2015, 257 million people were living with chronic hepatitis B infection, and in 2016, while 4.5 million (16.7%) of the people were diagnosed with hepatitis B . Hepatitis B can be prevented by safe and effective vaccines. Additionally, the WHO aims for eliminating viral hepatitis infections which include 90% reduction of new infections, 65% reduction in deaths resulting from viral hepatitis infections worldwide by 2030.

However, factors such as longer development and approval time for hepatitis drugs is expected to hinder growth of the hepatitis drugs market during the forecast period. For instance, according to the National Center for Biotechnology Information 2017, the development of a new medicine for hepatitis from target identification through approval for marketing, takes 12 years or longer.

Key features of the study

This report provides in-depth analysis of the hepatitis drugs market, market size (USD Mn), and Compound Annual Growth Rate (CAGR (%)) for the forecast period: 2026 - 2033, considering 2025 as the base year
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by leading players
It profiles key players in the global hepatitis drugs market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
Key players covered as a part of this study include Merck & Co. Inc., Gilead Sciences Inc., AbbVie Inc., Bristol Myers Squibb Company, F. Hoffmann-La Roche Ltd., LAURUS Labs, Zydus Cadila, Hetero Healthcare Limited, GlaxoSmithKline PLC., and Cipla Inc.
Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
The global hepatitis drugs market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for hepatitis drugs market, research and consulting firms, new entrants, and financial analysts

Market Segmentation

Drug Class Insights (Revenue, USD Mn, 2026 - 2033)
- Interferon Alphas
- HIV NRTIs
- Nucleotide Polymerase / NS5A Inhibitor Combinations
- Hepatitis C Protease / NS5A Inhibitor Combinations
- NS5A Inhibitors
- Nucleotide Polymerase Inhibitors
- Nucleoside Analogue Antivirals
- Thrombopoiesis Stimulating Agents
Disease Type Insights (Revenue, USD Mn, 2026 - 2033)
- Hepatitis B
- Hepatitis C
- Others
Route of Administration Insights (Revenue, USD Mn, 2026 - 2033)
- Oral
- Injection
Distribution Channel Insights (Revenue, USD Mn, 2026 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Regional Insights (Revenue, USD Mn, 2026 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
Key Players Insights
- Merck & Co. Inc.
- Gilead Sciences Inc.
- AbbVie Inc.
- Bristol Myers Squibb Company
- Hoffmann-La Roche Ltd.
- LAURUS Labs, Zydus Cadila
- Hetero Healthcare Limited
- GlaxoSmithKline PLC.
- Cipla Inc

1. Research Objective and Assumption

Research Objectives
Assumptions
Abbreviations

2. Market Overview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Drug Class
- Market Snippet, By Disease Type
- Market Snippet, By Route of Administration
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Market Trends
Key Developments
Regulatory Landscape
Epidemiology Analysis
Reimbursement Scenario
PEST Analysis

4. Global Hepatitis Drugs Market, By Drug Class, 2026-2033, (USD Mn)

Introduction
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Interferon Alphas
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
HIV NRTIs
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Nucleotide Polymerase / NS5A Inhibitor Combinations
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Hepatitis C Protease / NS5A Inhibitor Combinations
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
NS5A Inhibitors
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Nucleotide Polymerase Inhibitors
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Nucleoside Analogue Antivirals
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Thrombopoiesis Stimulating Agents
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends

5. Global Hepatitis Drugs Market, By Disease Type, 2026-2033, (USD Mn)

Introduction
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Hepatitis B
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Hepatitis C
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Others
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends

6. Global Hepatitis Drugs Market, By Route of Administration, 2026-2033, (USD Mn)

Introduction
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Oral
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Injection
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends

7. Global Hepatitis Drugs Market, By Distribution Channel, 2026-2033, (USD Mn)

Introduction
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Hospital Pharmacies
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Retail Pharmacies
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Online Pharmacies
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends

8. Global Hepatitis Drugs Market, By Region, 2026-2033, (USD Mn)

Introduction
- Market Share Analysis, By Region, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, For Region, 2021 - 2033
North America
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Drug Class, 2026-2033, (USD Mn)
- Market Size and Forecast, By Disease Type, 2026-2033, (USD Mn)
- Market Size and Forecast, By Route of Administration, 2026-2033, (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2026-2033, (USD Mn)
- Market Size and Forecast, By Country, 2026-2033, (USD Mn)
  - U.S.
  - Canada
Europe
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Drug Class, 2026-2033, (USD Mn)
- Market Size and Forecast, By Disease Type, 2026-2033, (USD Mn)
- Market Size and Forecast, By Route of Administration, 2026-2033, (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2026-2033, (USD Mn)
- Market Size and Forecast, By Country, 2026-2033, (USD Mn)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Drug Class, 2026-2033, (USD Mn)
- Market Size and Forecast, By Disease Type, 2026-2033, (USD Mn)
- Market Size and Forecast, By Route of Administration, 2026-2033, (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2026-2033, (USD Mn)
- Market Size and Forecast, By Country, 2026-2033, (USD Mn)
  - China
  - Japan
  - India
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Latin America
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Drug Class, 2026-2033, (USD Mn)
- Market Size and Forecast, By Disease Type, 2026-2033, (USD Mn)
- Market Size and Forecast, By Route of Administration, 2026-2033, (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2026-2033, (USD Mn)
- Market Size and Forecast, By Country, 2026-2033, (USD Mn)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Africa
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Drug Class, 2026-2033, (USD Mn)
- Market Size and Forecast, By Disease Type, 2026-2033, (USD Mn)
- Market Size and Forecast, By Route of Administration, 2026-2033, (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2026-2033, (USD Mn)
- Market Size and Forecast, By Country, 2026-2033, (USD Mn)
  - North Africa
  - Central Africa
  - South Africa
Middle East
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Drug Class, 2026-2033, (USD Mn)
- Market Size and Forecast, By Disease Type, 2026-2033, (USD Mn)
- Market Size and Forecast, By Route of Administration, 2026-2033, (USD Mn)
- Market Size and Forecast, By Distribution Channel, 2026-2033, (USD Mn)
- Market Size and Forecast, By Country, 2026-2033, (USD Mn)
  - GCC Countries
  - Israel
  - Rest of Middle East

9. Competitive Landscape

Company Profiles
- Merck & Co. Inc.
  - Company Overview
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Strategies
- Gilead Sciences Inc.
  - Company Overview
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Strategies
- AbbVie Inc.
  - Company Overview
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Strategies
- Bristol Myers Squibb Company
  - Company Overview
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Strategies
- F. Hoffmann-La Roche Ltd.
  - Company Overview
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Strategies
- LAURUS Labs
  - Company Overview
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Strategies
- Zydus Cadila
  - Company Overview
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Strategies
- Hetero Healthcare Limited
  - Company Overview
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Strategies
- GlaxoSmithKline PLC.
  - Company Overview
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Strategies
- Cipla Inc.
  - Company Overview
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Strategies
  - Analyst Views